|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 800 10th STREET, NW |
Address2 | Two City Center, Suite 400 |
City | WASHINGTON |
State | DC |
Zip Code | 20001-4956 |
Country | USA |
3. Principal place of business (if different than line 2)
City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 2571-12
|
||||||||
|
6. House ID# 306350000
|
TYPE OF REPORT | 8. Year | 2019 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Thomas P Nickels |
Date | 4/22/2019 5:25:09 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Discussions on drug pricing, 340b, and price transparency policies, as well as the International Pricing Index ANPRM; Discussions about the work of Aligning for Health to address social determinants of health; Support HR 1041 / S 586,Critical Access Hospital Relief Act of 2019, a bill to amend title XVIII of the Social Security Act to remove the 96-hour physician certification requirement for inpatient critical access hospital services; Support S 895, Rural Hospital Regulatory Relief Act of 2019, a bill to provide for a permanent extension of the enforcement instruction on supervision requirements for outpatient therapeutic services in critical access and small rural hospitals; Support S 948,Conrad State 30 and Physician Access Reauthorization Act, a bill to provide incentives to physicians to practice in rural and medically underserved communities, and for other purposes; Discussions in support of the Rural Emergency Medical Center Act (REACH) Act; Support for extension of the Rural Community Hospital Demonstration Program; Support for extension of the Frontier Community Health Integration Project Demonstration program; Discuss changes with House and Senate committees to Section 8122 of the SUPPORT for Patients and Communities Act; Letter of support to Energy and Commerce Committee for the hearing on legislation to strengthen our health care system and ACA market stability; Letter urging the Centers for Medicare & Medicaid Services (CMS)to consider alternative payment solutions for Chimeric Antigen Receptor T-cell (CAR T) therapy; Joint letter urging Congress to delay the start of the Medicaid disproportionate share hospital (DSH) cuts, which are scheduled to begin in fiscal year (FY) 2020; Comments to CMS on exploring ways continually to improve the Medicaid managed care program to ensure access to high-quality care for the Medicaid population.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Robyn |
Bash |
|
|
|
Megan |
Cundari |
|
|
|
Aimee Hartlage |
Kuhlman |
|
|
|
Thomas |
Nickels |
|
|
|
Erik |
Rasmussen |
|
|
|
Mike |
Rock |
|
|
|
Priscilla |
Ross |
|
|
|
Mark |
Seklecki |
|
|
|
Lawrence |
Hughes |
|
|
|
Maureen |
Mudron |
|
|
|
Rochelle |
Archuleta |
|
|
|
Akin |
Demehin |
|
|
|
Nancy |
Foster |
|
|
|
Joanna |
Kim |
|
|
|
Molly Collins |
Offner |
|
|
|
Roslyne |
Schulman |
|
|
|
Ashley |
Thompson |
|
|
|
Chantal |
Worzala |
|
|
|
Kristina |
Weger |
|
|
|
Travis |
Robey |
|
|
|
Lisa Kidder |
Hrobsky |
|
|
|
Molly |
Smith |
|
|
|
Shira |
Hollander |
|
|
|
Aaron |
Wesolowski |
|
|
|
Ariel |
Levin |
|
|
|
Erika |
Rogan |
|
|
|
Mark |
Howell |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Support HR 1763/ S 348, Resident Physician Shortage Reduction Act of 2019, a bill to amend title XVIII of the Social Security Act to provide for the distribution of additional residency positions; Oppose HR 506,Hospital Competition Act of 2019, a bill to amend title XVIII of the Social Security Act to increase hospital competition; Statement submitted to the House Judiciary on the hearing "Diagnosing the Problem: Exploring the Effects of Consolidation and Anticompetitive Conduct in Health Care Markets";Letter of support for the Senate Workgroups efforts to ensure consumer protections by addressing surprise medical bills and comments on the development of legislation to protect patients from surprise medical bills; Letter urging Congress and the Administration to take further action to help reduce input and administrative costs, as well as maximize the number of insured patients; Comment letter urged CMS to extend the comment period for the proposed rules related to interoperability provisions of the 21st Century Cures Act by at least 30 days; Comment letter on the Food and Drug Administrations (FDA) draft guidance on blood glucose monitoring test systems (BGMS) for prescription point-of-care (POC) use and urge FDA to consider compiling a finite list of universally acceptable disinfectant products that would apply to all medical devices or classes of device; Comment letter that urged CMS to address the substantial flaws in the star ratings methodology since the ratings inception in 2016 and to suspend the display of overall star ratings on Hospital Compare while the agency continues its important work of enhancing the validity and meaningfulness of star ratings; Comment letter to FDA on the public meeting, Identifying the Root Causes of Drug Shortages and Finding Enduring Solutions with the following legislative recommendations: Strengthen manufacturers drug shortage disclosure requirements, Incentivize manufacturing contingency plans and/or redundancies, Enhance production transparency requirements, Enact shortage disclosure notification requirements for certain medical devices needed to administer drugs, Assess drug shortages as a national security threat, Include potential risk for drug shortages as a factor in the Federal Trade Commission (FTC) reviews of drug company merger proposals, and regulatory recommendations: Establish incentives to encourage manufacturers to produce drugs in shortage, Prevent manufacturing shutdowns, Establish a quality manufacturing initiative, Enhance information on the quality of outsourcing facilities compounding, Expand and improve the FDAs drug shortages list, Develop a list of critical drugs, Consider how reducing the number of unapproved drugs1 on the market might impact shortages, Reduce drug waste, Create an Office of Clinical Affairs within the Drug Enforcement Administration (DEA); Comment letter urging the CMS to use its upcoming proposed rules for Inpatient Rehabilitation Facility (IRF) and other post-acute care providers to address several issues related to the implementation of the revised case-mix grouping (CMG) policies.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), White House Office
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Robyn |
Bash |
|
|
|
Megan |
Cundari |
|
|
|
Aimee Hartlage |
Kuhlman |
|
|
|
Thomas |
Nickels |
|
|
|
Erik |
Rasmussen |
|
|
|
Mike |
Rock |
|
|
|
Priscilla |
Ross |
|
|
|
Mark |
Seklecki |
|
|
|
Lawrence |
Hughes |
|
|
|
Maureen |
Mudron |
|
|
|
Rochelle |
Archuleta |
|
|
|
Akin |
Demehin |
|
|
|
Nancy |
Foster |
|
|
|
Joanna |
Kim |
|
|
|
Molly Collins |
Offner |
|
|
|
Roslyne |
Schulman |
|
|
|
Ashley |
Thompson |
|
|
|
Chantal |
Worzala |
|
|
|
Kristina |
Weger |
|
|
|
Travis |
Robey |
|
|
|
Lisa Kidder |
Hrobsky |
|
|
|
Molly |
Smith |
|
|
|
Shira |
Hollander |
|
|
|
Aaron |
Wesolowski |
|
|
|
Ariel |
Levin |
|
|
|
Erika |
Rogan |
|
|
|
Mark |
Howell |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code LAW
16. Specific lobbying issues
Meeting with CMS and HHS OIG to relate continuing methodological issues and other errors with the OIG audits targeting hospitals for potential Medicare overpayments and to urge significant reforms of the auditing process including discontinuing use of extrapolation; Discussions on the work/fixes to the anti-kickback provisions in the Eliminating Kickback in Recovery Act of 2018.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Federal Trade Commission (FTC), Justice - Dept of (DOJ), Veterans Affairs - Dept of (VA), Office of Management & Budget (OMB), Health & Human Services - Dept of (HHS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Robyn |
Bash |
|
|
|
Megan |
Cundari |
|
|
|
Aimee Hartlage |
Kuhlman |
|
|
|
Thomas |
Nickels |
|
|
|
Erik |
Rasmussen |
|
|
|
Mike |
Rock |
|
|
|
Priscilla |
Ross |
|
|
|
Mark |
Seklecki |
|
|
|
Lawrence |
Hughes |
|
|
|
Maureen |
Mudron |
|
|
|
Rochelle |
Archuleta |
|
|
|
Akin |
Demehin |
|
|
|
Nancy |
Foster |
|
|
|
Joanna |
Kim |
|
|
|
Molly Collins |
Offner |
|
|
|
Roslyne |
Schulman |
|
|
|
Ashley |
Thompson |
|
|
|
Chantal |
Worzala |
|
|
|
Kristina |
Weger |
|
|
|
Travis |
Robey |
|
|
|
Lisa Kidder |
Hrobsky |
|
|
|
Molly |
Smith |
|
|
|
Shira |
Hollander |
|
|
|
Aaron |
Wesolowski |
|
|
|
Ariel |
Levin |
|
|
|
Erika |
Rogan |
|
|
|
Mark |
Howell |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
Continue to monitor the FY 2019 budget to prevent or minimize hospital cuts.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, White House Office, Office of Management & Budget (OMB)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Robyn |
Bash |
|
|
|
Megan |
Cundari |
|
|
|
Aimee Hartlage |
Kuhlman |
|
|
|
Thomas |
Nickels |
|
|
|
Erik |
Rasmussen |
|
|
|
Mike |
Rock |
|
|
|
Priscilla |
Ross |
|
|
|
Mark |
Seklecki |
|
|
|
Lawrence |
Hughes |
|
|
|
Maureen |
Mudron |
|
|
|
Rochelle |
Archuleta |
|
|
|
Akin |
Demehin |
|
|
|
Nancy |
Foster |
|
|
|
Joanna |
Kim |
|
|
|
Molly Collins |
Offner |
|
|
|
Roslyne |
Schulman |
|
|
|
Ashley |
Thompson |
|
|
|
Chantal |
Worzala |
|
|
|
Kristina |
Weger |
|
|
|
Travis |
Robey |
|
|
|
Lisa Kidder |
Hrobsky |
|
|
|
Molly |
Smith |
|
|
|
Aaron |
Wesolowski |
|
|
|
Shira |
Hollander |
|
|
|
Ariel |
Levin |
|
|
|
Erika |
Rogan |
|
|
|
Mark |
Howell |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
Monitoring the Tax Cuts and Jobs Act, legislation to overhaul the nations tax code that contains several notable provisions affecting hospitals; Individual Mandate, Access to Tax-exempt Bond Financing, Interest Deduction for Debt, Medical Expense Deductions, Executive Compensation.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Internal Revenue Service (IRS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Robyn |
Bash |
|
|
|
Megan |
Cundari |
|
|
|
Aimee Hartlage |
Kuhlman |
|
|
|
Thomas |
Nickels |
|
|
|
Erik |
Rasmussen |
|
|
|
Mike |
Rock |
|
|
|
Priscilla |
Ross |
|
|
|
Mark |
Seklecki |
|
|
|
Lawrence |
Hughes |
|
|
|
Maureen |
Mudron |
|
|
|
Rochelle |
Archuleta |
|
|
|
Akin |
Demehin |
|
|
|
Nancy |
Foster |
|
|
|
Joanna |
Kim |
|
|
|
Molly Collins |
Offner |
|
|
|
Roslyne |
Schulman |
|
|
|
Ashley |
Thompson |
|
|
|
Chantal |
Worzala |
|
|
|
Kristina |
Weger |
|
|
|
Travis |
Robey |
|
|
|
Lisa Kidder |
Hrobsky |
|
|
|
Molly |
Smith |
|
|
|
Shira |
Hollander |
|
|
|
Aaron |
Wesolowski |
|
|
|
Ariel |
Levin |
|
|
|
Erika |
Rogan |
|
|
|
Mark |
Howell |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address |
|
||||||
City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
LBR |
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
Lobbyist Name | Description of Offense(s) |